Ibcef 500 Tablet contains Cefuroxime 500 mg, a second-generation cephalosporin antibiotic effective against a broad spectrum of bacterial infections. Cefuroxime exerts its bactericidal action by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. This medication is indicated for the treatment of respiratory tract infections such as bronchitis and pneumonia, urinary tract infections, skin and soft tissue infections, and Lyme disease. Ibcef 500 is also utilized in managing infections caused by susceptible strains of both Gram-positive and Gram-negative bacteria. The tablet formulation ensures convenient oral administration with good bioavailability. Dosage and duration of therapy should be determined based on the severity of infection, patient age, renal function, and clinical response. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, as well as hypersensitivity reactions in patients with a history of beta-lactam allergy. Caution is advised in patients with renal impairment, and dose adjustment may be necessary. Ibcef 500 should be used under medical supervision with adherence to prescribed dosage to prevent the development of bacterial resistance. It is contraindicated in individuals with known hypersensitivity to cephalosporins or penicillins.